1.Dowden, Helen, and Jamie Munro. “Trends in clinical success rates and therapeutic focus.” Nat. Rev. Drug Discov 18.7 (2019): 495-6.
2.Hwang, Thomas J., et al. “Failure of investigational drugs in late-stage clinical development and publication of trial results.” JAMA internal medicine 176.12 (2016): 1826-1833.
3.Lee, Hye Won, et al. “Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.” Genome medicine 12.1 (2020): 1-21.
4.Veninga, Vivien, and Emile E. Voest. “Tumor organoids: opportunities and challenges to guide precision medicine.” Cancer Cell 39.9 (2021): 1190-1201.
5.Cobain, Erin F., et al. “Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors.” JAMA oncology 7.4 (2021): 525-533.
6.Li, Hongyi, et al. “Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.” Signal transduction and targeted therapy 5.1 (2020): 1-23.
7.Shiihara, Masahiro, and Toru Furukawa. “Application of Patient-Derived Cancer Organoids to Personalized Medicine.” Journal of Personalized Medicine 12.5 (2022): 789.
8.Ben-David, Uri, et al. “Genetic and transcriptional evolution alters cancer cell line drug response.” Nature 560.7718 (2018): 325-330.
9.Ren, Ya, et al. “Developments and opportunities for 3D bioprinted organoids.” International Journal of Bioprinting 7.3 (2021).
10.Huch, Meritxell, and Bon-Kyoung Koo. “Modeling mouse and human development using organoid cultures.” Development 142.18 (2015): 3113-3125.
11.Schutgens, Frans, and Hans Clevers. “Human organoids: tools for understanding biology and treating diseases.” Annual Review of Pathology: Mechanisms of Disease 15 (2020): 211-234.
12.Wang, Qinying, et al. “Applications of human organoids in the personalized treatment for digestive diseases.” Signal Transduction and Targeted Therapy 7.1 (2022): 1-30.
13.Assawachananont, Juthaporn, et al. “Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice.” Stem cell reports 2.5 (2014): 662-674.
14.McCracken, Kyle W., et al. “Modelling human development and disease in pluripotent stem-cell-derived gastric organoids.” Nature 516.7531 (2014): 400-404.
15.Spence, Jason R., et al. “Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro.” Nature 470.7332 (2011): 105-109.
16.Chen, Kevin G., et al. “Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.” Drug discovery today 24.11 (2019): 2126-2138.
17.Nozaki, Kengo, et al. “Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes.” Journal of gastroenterology 51.3 (2016): 206-213.‏
18.Ben-David, Uri, et al. “Genetic and transcriptional evolution alters cancer cell line drug response.” Nature 560.7718 (2018): 325-330.
19.Ghajari, Ghazal, Arefe Heydari, and Masoud Ghorbani. “Mesenchymal stem cell-based therapy and female infertility: limitations and advances.” Current Stem Cell Research & Therapy (2022).
20.Ben-David, Uri, et al. “Patient-derived xenografts undergo mouse-specific tumor evolution.” Nature genetics 49.11 (2017): 1567-1575.
21.Broutier, Laura, et al. “Human primary liver cancer–derived organoid cultures for disease modeling and drug screening.” Nature medicine 23.12 (2017): 1424-1435.
22.Boj, Sylvia F., et al. “Organoid models of human and mouse ductal pancreatic cancer.” Cell 160.1-2 (2015): 324-338.
23.Broutier, Laura, et al. “Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation.” Nature protocols 11.9 (2016): 1724-1743.
24.Van de Wetering, Marc, et al. “Prospective derivation of a living organoid biobank of colorectal cancer patients.” Cell 161.4 (2015): 933-945.
25.Kim, Minsuh, et al. “Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.” Nature communications 10.1 (2019): 1-15.
26.Wong, Chi Heem, Kien Wei Siah, and Andrew W. Lo. “Estimation of clinical trial success rates and related parameters.” Biostatistics 20.2 (2019): 273-286.
27.Veninga, Vivien, and Emile E. Voest. “Tumor organoids: opportunities and challenges to guide precision medicine.” Cancer Cell 39.9 (2021): 1190-1201.
28.Kretzschmar, Kai. “Cancer research using organoid technology.” Journal of Molecular Medicine 99.4 (2021): 501-515.
29.Drost, Jarno, and Hans Clevers. “Organoids in cancer research.” Nature Reviews Cancer 18.7 (2018): 407-418.
30.Kodack, David P., et al. “Primary patient-derived cancer cells and their potential for personalized cancer patient care.” Cell reports 21.11 (2017): 3298-3309.
31.de Witte, Chris Jenske, et al. “Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses.” Cell reports 31.11 (2020): 107762.
32.Ooft, S. N., et al. “Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.” ESMO open 6.3 (2021): 100103.
33.Huang, Ling, et al. “Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids.” Nature medicine 21.11 (2015): 1364-1371.
34.Karthaus, Wouter R., et al. “Identification of multipotent luminal progenitor cells in human prostate organoid cultures.” Cell 159.1 (2014): 163-175.
35.Dijkstra, Krijn K., et al. “Patient-derived organoid models of human neuroendocrine carcinoma.” Frontiers in endocrinology 12 (2021): 627819.
36.Patel, Tushar. “Worldwide trends in mortality from biliary tract malignancies.” BMC cancer 2.1 (2002): 1-5.‏
37.Khan, Shahid A., et al. “Changing international trends in mortality rates for liver, biliary and pancreatic tumours.” Journal of hepatology 37.6 (2002): 806-813.
38.Carriaga, Marisa T., and Donald Earl Henson. “Liver, gallbladder, extrahepatic bile ducts, and pancreas.” Cancer 75.S1 (1995): 171-190.
39.Abou-Alfa, Ghassan K., et al. “Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.” The Lancet Oncology 21.6 (2020): 796-807.‏
40.Unno, Michiaki, Tatsuo Hata, and Fuyuhiko Motoi. “Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.” Surgery today 49.4 (2019): 295-299.
41.Biankin, Andrew V., et al. “Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.” Nature 491.7424 (2012): 399-405.
42.Dalton, W. Brian. DNA damage during mitotic arrest: A novel, p53-regulated source of structural chromosome instability in human cells. Diss. Emory University, 2008.
43.Shiihara, Masahiro, et al. “Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.” European Journal of Cancer 148 (2021): 239-250.
44.Seino, Takashi, et al. “Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression.” Cell stem cell 22.3 (2018): 454-467.
45.Jusakul, Apinya, et al. “Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of CholangiocarcinomaIntegrative Genomic and Epigenomic Analysis of Cholangiocarcinoma.” Cancer discovery 7.10 (2017): 1116-1135.
46.Driehuis, Else, et al. “Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.” Proceedings of the National Academy of Sciences 116.52 (2019): 26580-26590.
47.Hu, Tuo, et al. “Metabolic rewiring by loss of Sirt5 promotes Kras-induced pancreatic cancer progression.” Gastroenterology 161.5 (2021): 1584-1600.
48.Fujiwara, Hiroaki, et al. “5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids.” Surgical Oncology 35 (2020): 484-490.
49.Tsai, Susan, et al. “Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.” BMC cancer 18.1 (2018): 1-13.
50.Koikawa, Kazuhiro, et al. “Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.” Cell 184.18 (2021): 4753-4771.
51.Öhlund, Daniel, et al. «Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.» Journal of Experimental Medicine 214.3 (2017): 579-596.
52.Grandori, Carla, and Christopher J. Kemp. “Personalized cancer models for target discovery and precision medicine.” Trends in cancer 4.9 (2018): 634-642.
53.Nussinov, Ruth, et al. “Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers.” PLoS computational biology 15.3 (2019): e1006658.
54.Saito, Yoshimasa, et al. “Establishment of patient-derived organoids and drug screening for biliary tract carcinoma.” Cell reports 27.4 (2019): 1265-1276.
55.Pauli, Chantal, et al. “Personalized In Vitro and In Vivo Cancer Models to Guide Precision MedicinePersonalized Cancer Models to Guide Precision Medicine.” Cancer discovery 7.5 (2017): 462-477.
56.Larsen, Brian M., et al. “A pan-cancer organoid platform for precision medicine.” Cell reports 36.4 (2021): 109429.
57.Narasimhan, Vignesh, et al. “Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized TherapyFunctional Precision Medicine for Advanced Colorectal Cancer.” Clinical Cancer Research 26.14 (2020): 3662-3670.
58.Gilles, Maud-Emmanuelle, et al. “Personalized RNA medicine for pancreatic cancer.” Clinical Cancer Research 24.7 (2018): 1734-1747.
59.Tung, Kuei-Ling, et al. “Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance.” Genes & diseases 8.2 (2021): 203-214.
60.Broutier, Laura, et al. “Human primary liver cancer–derived organoid cultures for disease modeling and drug screening.” Nature medicine 23.12 (2017): 1424-1435.
61.Neal, James T., et al. “Organoid modeling of the tumor immune microenvironment.” Cell 175.7 (2018): 1972-1988.
62.Schnalzger, Theresa E., et al. “3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids.” The EMBO journal 38.12 (2019): e100928.
63.Forsythe, Steven D., et al. “Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility StudyImmunotherapy Efficacy in Appendiceal Cancer Organoids.” Clinical Cancer Research 27.18 (2021): 5141-5150.
64.Votanopoulos, Konstantinos I., et al. “Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study.” Annals of surgical oncology 26.1 (2019): 139-147.
65.Nuciforo, Sandro, et al. “Organoid models of human liver cancers derived from tumor needle biopsies.” Cell reports 24.5 (2018): 1363-1376.
66.Pasch, Cheri A., et al. “Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation.” Clinical Cancer Research 25.17 (2019): 5376-5387.